VivoSeq
Neurology

Compartment Syndrome

7

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Compartment Syndrome is an early-stage landscape with 7 programs across 6 companies. The most active players are Pfizer, Vitae Pharmaceuticals Inc., an Allergan affiliate, Microvascular Therapeutics, LLC. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

57/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2M

Microvascular Therapeutics, LLC

1 program

Phase 3M

Milestone Pharmaceuticals Inc.

1 program

ApprovedAbbVie logo

AbbVie

1 program

ApprovedGSK logo

GSK

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

9

clinical trials

Completed4 · 44%
Terminated3 · 33%
Unknown status1 · 11%
Active, not recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

BM-MNCs for Lower Extremity Compartment Syndrome Injury
Active, not recruiting·OOregon Health and Science University·Phase 1·NCT03880656·18 enrolled
Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers
Completed·—·Phase 1·NCT04113954·42 enrolled
Comparison of Non-Surgical Treatment Options for Chronic Exertional Compartment Syndrome (CECS)
Completed·WWalter Reed National Military Medical Center·Phase 2·NCT04409600·35 enrolled
Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A
Completed·EEmory University·Phase 4·NCT05466539·3 enrolled
Diagnosing Compartment Syndrome With SHAPE vs Elastography
Completed·TThomas Jefferson University·Phase 2/3·NCT05247541·15 enrolled
Botulinum for Chronic Exertional Compartment Syndrome
Terminated·3375th Medical Group, Scott Air Force Base·Phase 2/3·NCT03339921·3 enrolled
Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome
Terminated·UUniversity of Wisconsin, Madison·Phase 4·NCT05006417·1 enrolled
Botox for the Treatment of Chronic Exertional Compartment Syndrome
Terminated·UUniversity of Wisconsin, Madison·Phase 1/2·NCT03922139·7 enrolled
Treatment of Lower Leg Anterolateral Chronic Exertional Compartment Syndrome With Intra-muscular Botulinum Injections.
Unknown status·UUniversity of Calgary·N/A·NCT05765071·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)